First-Line Treatment Patterns of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) with and without BRAF Mutations in the US

被引：0
|
作者：
Vieira, M. Cecilia [1 ]
Duncan, K. [1 ]
Hsu, W. -C. [2 ]
Ross, R. [2 ]
Benjumea, D. [2 ]
Vlahiotis, A. [1 ]
Li, B. [1 ]
Wilner, K. D. [3 ]
机构：
[1] Pfizer Inc, New York, NY USA
[2] Genesis Res LLC, Hoboken, NJ USA
[3] Pfizer Inc, San Diego, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.61
引用
收藏
页码：E36 / E36
页数：1
相关论文
共 50 条
  • [11] Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer
    Santarpia, Mariacarmela
    Menis, Jessica
    Chaib, Imane
    Cao, Maria Gonzalez
    Rosell, Rafael
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 831 - 840
  • [12] Pembrolizumab for the first-line treatment of non-small cell lung cancer
    Ninomiya, Kiichiro
    Hotta, Katsuyuki
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (10) : 1015 - 1021
  • [13] Pemetrexed in first-line treatment of non-small cell lung cancer
    Esteban, Emilio
    Casillas, Marta
    Cassinello, Alejo
    CANCER TREATMENT REVIEWS, 2009, 35 (04) : 364 - 373
  • [14] Patterns of failure in metastatic non-small cell lung cancer (mNSCLC) treated with first line pembrolizumab and use of local therapy in patients with oligoprogression
    Friedes, Cole
    Yegya-Raman, Nikhil
    Zhang, Siqi
    Iocolano, Michelle
    Cohen, Roger B.
    Aggarwal, Charu
    Thompson, Jeffrey C.
    Marmarelis, Melina Elpi
    Levin, William C.
    Cengel, Keith A.
    Ciunci, Christine Agnes
    Singh, Aditi Puri
    Davella, Christopher
    Davis, Christiana
    Langer, Corey J.
    Feigenberg, Steven J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [15] Afatinib vs. Osimertinib as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Hoang, T. T. A.
    Nguyen, T. T. T.
    Pham, C. T. M.
    Dong, H. Q.
    Nguyen, K. T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S626 - S627
  • [16] Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the US
    Chopra, Divyan
    Waterhouse, David M.
    Sultan, Ihtisham
    Stollenwerk, Bjorn
    CURRENT ONCOLOGY, 2025, 32 (03)
  • [17] Predictive model for response to first-line treatment for metastatic non-small cell lung cancer.
    Badawy, Ahmed Ashour
    Bae, Sejong
    Omar, Abbas
    Arafat, Waleed O.
    Khedr, Gehan Abd Elatti
    Grant, Stefan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [18] Immunotherapy as first-line treatment in metastatic non-small cell lung cancer: A single center experience
    Rauthan, A.
    Patil, P.
    Lahkar, K.
    Murthy, N. Y.
    Vundemodalu, P.
    Ashwath, R.
    Jomi, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S1576 - S1576
  • [19] Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer
    Stares, Mark
    Swan, Amanda
    Cumming, Kirsten
    Ding, Tze-En
    Leach, James
    Stratton, Cory
    Thomson, Findlay
    Barrie, Colin
    MacLennan, Kirsty
    Campbell, Sorcha
    Evans, Tamasin
    Tufail, Aisha
    Harrow, Stephen
    MacKean, Melanie
    Phillips, Iain
    FRONTIERS IN NUTRITION, 2021, 8
  • [20] Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancer
    Kaya, Ali Osman
    Buyukberber, Suleyman
    Dane, Faysal
    Isikdogan, Abdurrahman
    Ustaalioglu, Basak Oven
    Coskun, Ugur
    Yumuk, Perran Fulden
    Dogu, Gamze Gokoz
    Ozdemir, Nuriye Yildirim
    Sevinc, Alper
    Gumus, Mahmut
    Ozkan, Metin
    Yildiz, Ramazan
    Ozturk, Banu
    Yaman, Emel
    Benekli, Mustafa
    TUMORI JOURNAL, 2010, 96 (03): : 400 - 404
12345